[go: up one dir, main page]

WO1994025014A1 - Traitement de la cholelithiase avec des beta-2-agonistes - Google Patents

Traitement de la cholelithiase avec des beta-2-agonistes Download PDF

Info

Publication number
WO1994025014A1
WO1994025014A1 PCT/GB1994/000566 GB9400566W WO9425014A1 WO 1994025014 A1 WO1994025014 A1 WO 1994025014A1 GB 9400566 W GB9400566 W GB 9400566W WO 9425014 A1 WO9425014 A1 WO 9425014A1
Authority
WO
WIPO (PCT)
Prior art keywords
management
cholelithiasis
smooth muscle
salbutamol
muscle relaxant
Prior art date
Application number
PCT/GB1994/000566
Other languages
English (en)
Inventor
George Henry Wright
Original Assignee
George Henry Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Henry Wright filed Critical George Henry Wright
Priority to EP94909985A priority Critical patent/EP0695178A1/fr
Priority to AU62613/94A priority patent/AU6261394A/en
Publication of WO1994025014A1 publication Critical patent/WO1994025014A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Definitions

  • This invention relates to the management of cholelithiasis (gall stones) .
  • the present invention provides for the effective management of cholelithiasis. It consists in the administration of an effective amount of an agent which will raise the resting difference in potential across the plasma membrane of the smooth muscle cells in the wall of the gall bladder.
  • a preferred agent is a known smooth muscle relaxant, especially of the class known as S2-agonists. Most preferred amongst these is Salbutamol (2-tert-butylamino-l- (4-hydroxy-3- hydroxymethylphenyl) ethanol) .
  • Administration will preferably be orally.
  • the invention also provides for the use of such an agent, of a smooth muscle relaxant and in particular of a smooth muscle relaxant which is a ⁇ 2- agonist in the manufacture of a medicament for the management of cholelithiasis.
  • the medicament will be preferably in tablet form.
  • Such agents are known.
  • One of the earliest- known of the general class is ephedrine. This is effective in the present invention but is not specific and therefore has side-effects; pseudoephedrine is similar.
  • These and other general relaxants have been largely superceded by groups of relaxants which are targetted and indicated for various different specific organs of the body.
  • the ⁇ 2-agonists with which the present invention is particularly concerned are formulated and indicated for the treatment of asthma and as such are most commonly presented in aerosol or spray form, for inhalation by the patient.
  • tablet forms are also available. It is known that at least some &2-agonists, including Salbutamol, have an effect on the uterus and have been used for the inhibition of contractions during premature labour.
  • Salbutamol is the preferred S2- agonist relaxant used in this invention (examples of formulation being Ventolin from Glaxo, Salbuvent from Tillots, Salbulin from Riker and Volmax from Duncan Flockhart)
  • other ⁇ -agonists which may be used include those known under the generic names Salmeterol ( (RS) -5- ⁇ l-hydroxy-2- [6- (phenylbutoxy)hexylamino] ethyl ⁇ salinyl alcohol) , Orciprenaline (1- (3, 5-dihydroxyphenyl) -2- isopropylamino ethanol sulphate) , Terbutaline (2-tert- butylamino-1- (3, 5-dihydroxyphenyl) ethanol sulphate) , Fenoterol (1- (3, 5-Dihydroxyphenyl) -2- (4-hydroxy- ⁇ .- methylphenethylamino) ethanol hydrobromide) , Reproterol (7- ⁇ 3- [ (3 , 5, ⁇
  • the agent is preferably administered sublingually by tablet despite the fact that relief would not usually be experienced for some forty minutes.
  • Dosages may be in the range presently prescribed for asthma.
  • a single 4mg tablet of Salbutamol held sublingually will give relief to an average patient after a delay of some forty minutes, lasting for the whole of the usual duration of an episode which is about four hours.
  • Tenderness (inflammation) of the gall ⁇ bladder following an acute episode may be treated by steroids such as ⁇ -methazone by injection.
  • the chronic condition can be managed by the patient himself upon feeling the onset of an episode, preferably by sublingual tablet. As is conventional the patient should adopt a favourable regime and in particular avoid a high fat diet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'administration d'un β2-agoniste, en particulier de Salbutamol, pour traiter les crises de colique biliaire chez les individus souffrant de cholélithiase.
PCT/GB1994/000566 1993-04-23 1994-03-21 Traitement de la cholelithiase avec des beta-2-agonistes WO1994025014A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94909985A EP0695178A1 (fr) 1993-04-23 1994-03-21 Traitement de la cholelithiase avec des beta-2-agonistes
AU62613/94A AU6261394A (en) 1993-04-23 1994-03-21 Management of cholelithiasis with beta-2-agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939308469A GB9308469D0 (en) 1993-04-23 1993-04-23 Management of cholelithiasis
GB9308469.7 1993-04-23

Publications (1)

Publication Number Publication Date
WO1994025014A1 true WO1994025014A1 (fr) 1994-11-10

Family

ID=10734387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/000566 WO1994025014A1 (fr) 1993-04-23 1994-03-21 Traitement de la cholelithiase avec des beta-2-agonistes

Country Status (4)

Country Link
EP (1) EP0695178A1 (fr)
AU (1) AU6261394A (fr)
GB (1) GB9308469D0 (fr)
WO (1) WO1994025014A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032964A3 (fr) * 2001-10-17 2003-11-27 Univ Wales College Of Medecine Jonctions lacunaires et edhf

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358144A1 (fr) * 1976-07-13 1978-02-10 Lipha Nouvelle composition medicamenteuse pour le traitement de la lithiase biliaire
EP0400219A2 (fr) * 1989-06-01 1990-12-05 Taiko Pharmaceutical Co., Ltd. Utilisation de créosote comme agent antispasmodique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358144A1 (fr) * 1976-07-13 1978-02-10 Lipha Nouvelle composition medicamenteuse pour le traitement de la lithiase biliaire
EP0400219A2 (fr) * 1989-06-01 1990-12-05 Taiko Pharmaceutical Co., Ltd. Utilisation de créosote comme agent antispasmodique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"ISOMETHEPTENE IN THE MANAGEMENT OF SOME PAINFUL GASTRO ENTEROLOGICAL DISORDERS", DIALOG FILE SUPPLIER; BIOSIS: AN=75051813 *
CHEMICAL ABSTRACTS, vol. 113, no. 19, 5 November 1990, Columbus, Ohio, US; abstract no. 164825a, KAJIYAMA G.: "ODDI'S SPHINCTER RELAXANTS-ACTION MECHANISM AND USES" *
CHIRYOGAKU, vol. 24, no. 5, 1990, pages 568 - 570 *
H. DARDIK ET AL.: "EXPERIMENTAL MANAGEMENT BY NONOPERATIVE ADRENERGIC STIMULATION OF SIMULATED COMMON DUCT STONES", THE AMERICAN JOURNAL OF DIGESTIVE DISEASES, vol. 16, no. 4, 1971, pages 321 - 326 *
J. KANTO ET AL.: "THE EFFECTS OF DRUGS WITH DIFFERENT MECHANISMS OF ACTION ON THE CONTRACTION OF THE HUMAN GALLBLADER", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY THERAPY AND TOXICOLOGY, vol. 19, no. 7, 1981, pages 303 - 309 *
J.E.F. REYNOLDS: "MARTINDALE, THE EXTRA PHARMACOPOEIA", 1989, THE PHARMACEUTICAL PRESS, LONDON *
M. SCHORDERET: "PHARMACOLOGIE", 1989, FRISON-ROCHE, PARIS *
NAIM U. ET AL., CLIN. TER., vol. 102, no. 3, 1982, pages 267 - 272 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032964A3 (fr) * 2001-10-17 2003-11-27 Univ Wales College Of Medecine Jonctions lacunaires et edhf

Also Published As

Publication number Publication date
AU6261394A (en) 1994-11-21
GB9308469D0 (en) 1993-06-09
EP0695178A1 (fr) 1996-02-07

Similar Documents

Publication Publication Date Title
Gersema et al. Use of corticosteroids in oral surgery
US5543434A (en) Nasal administration of ketamine to manage pain
DE69819748T2 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
JP3984787B2 (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
WO1990006110A1 (fr) Traitement de l'obesite
EP1051972A1 (fr) Compositions de donneurs d'oxyde nitrique et méthode pour le traitement de troubles anaux
HUP0104676A2 (en) Compositions for the treatment of anorectal disorders and their use
MXPA97003693A (en) Profilactic treatment of allergic dermatitis by conta
Eddy et al. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone)
WO2000025821A1 (fr) Methode permettant de traiter et de diagnostiquer le syndrome des impatiences des membres inferieurs et dispositif correspondant
JPH10512573A (ja) セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
Gerolami et al. Controlled trial of chenodeoxycholic therapy for radiolucent gallstones: A multicenter study
WO1994025014A1 (fr) Traitement de la cholelithiase avec des beta-2-agonistes
EP0171227A1 (fr) Utilisation de propiophénone
US6410560B1 (en) Drug for relieving pain and promoting the removal of calculi in urolithiasis
WO2024208166A1 (fr) Utilisation du sivelestat en analgésie
Cañadell-Carafi et al. Ketorolac, a new non-opioid analgesic: a single-blind trial versus buprenorphine in pain after orthopaedic surgery
CA2130770A1 (fr) Traitement des infections des voies respiratoires superieures
JP2004513916A (ja) 複合的な５−ｈｔ１ａアゴニストおよび選択的セロトニン再取り込み阻害剤の新規な使用
US4522827A (en) Method of treating acute pancreatitis with isometheptene
Edwards Orcipenaline in Treatment of Airways Obstruction in Chronic Bronchitis
Shutkin Clinical and experimental observations in peptic ulcer with a new, prolonged-acting anticholinergic drug.
Markowitz et al. Comparison of meclofenamate sodium with buffered aspirin and placebo in the treatment of postsurgical dental pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 530360

Date of ref document: 19951006

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1994909985

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994909985

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994909985

Country of ref document: EP